S-1: Biofrontera S-1: Selling Stockholders Offer 4M Shares

Biofrontera Inc. files an S-1 registration statement for the resale of 4,000,640 common shares by selling stockholders, with no proceeds going to the company.

Summary

• The filing registers 4,000,640 shares of common stock for resale by identified selling stockholders, which were issued upon the conversion of Series C Convertible Preferred Stock.
• Biofrontera Inc. will not receive any proceeds from the sale of these shares by the Selling Stockholders.
• The company is a U.S.-based biopharmaceutical firm focused on photodynamic therapy (PDT) for dermatological conditions, primarily actinic keratoses (AK).
• Its principal product is Ameluz, used in combination with the RhodoLED lamp series for PDT.
• On October 20, 2025, Biofrontera acquired all U.S. rights to Ameluz and RhodoLED from the Biofrontera Group, replacing a previous transfer pricing model with an earnout of 12% to 15% of U.S. revenues.
• In the fourth quarter of 2025, the company completed the sale of its Xepi product line for a maximum of $10,000,000, including $3,000,000 in cash paid on the closing date.
• The FDA approved an increased dosage of Ameluz from one to three tubes per treatment in October 2024, allowing for treatment of larger or multiple areas.
• A Supplemental New Drug Application (sNDA) for the treatment of superficial basal cell carcinoma with Ameluz was submitted to the FDA in November 2025.
• The company's common stock is quoted on the Nasdaq Capital Market under the symbol BFRI, with a last reported sale price of $0.81 on December 2, 2025.
• Biofrontera Inc. is classified as an emerging growth company and a smaller reporting company, allowing for reduced public company reporting requirements.

Sentiment

Score: 3

Explanation: While there are positive strategic moves like acquiring full product rights and expanding indications, the significant financial risks, including substantial doubt about the ability to continue as a going concern, persistent operating losses, substantial dilution from future conversions, and ongoing Nasdaq compliance issues, overshadow these positives, indicating a highly precarious financial position.

Positives

• The acquisition of all U.S. rights to Ameluz and RhodoLED allows for more effective cost management and direct oversight of clinical trial efficiency.
• The new earnout model (12-15% of U.S. revenues) replaces a higher transfer pricing model (25-35% of net sales), potentially improving the company's profitability.
• The divestment of the Xepi product line for up to $10,000,000 provides immediate cash ($3,000,000) and future earnout potential.
• FDA approval of increased Ameluz dosage (1 to 3 tubes) and the RhodoLED XL lamp enables treatment of larger areas and multiple lesions, enhancing market potential and treatment efficiency.
• New Ameluz formulation (propylene glycol-free) and pain-reduced PDT patents extend patent protection until 2043, 2039, and 2040, respectively.
• Ameluz PDT therapy demonstrates high effectiveness with up to 91% clearance after one or two treatments and limited or no scarring.
• The targeted market for Ameluz PDT, including conversion from cryotherapy, is estimated at $500 million, representing 11% of the total AK market.
• Submission of a Supplemental New Drug Application for superficial basal cell carcinoma expands potential indications for Ameluz.

Negatives

• The company will not receive any proceeds from the sale of 4,000,640 common shares by the selling stockholders, leading to dilution without capital infusion.
• Certain important patents for Ameluz expired in 2019, increasing the risk of generic competition and potential significant price reductions and market share loss.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of operating losses and anticipates continued losses, with no assurance of achieving sustained profitability.
• Dependence on a single unaffiliated contract manufacturer (with a second recently contracted) for Ameluz production poses a supply chain risk.
• Significant competition exists from other pharmaceutical and medical device companies, as well as established treatments like cryotherapy (86% market share) and topical medications (12% market share).
• The company received a Nasdaq notification on November 4, 2025, indicating potential delisting if compliance with Rule 5550(b)(1) (stockholders' equity) is not evidenced in its next periodic report.
• Future sales and issuances of common stock, including from outstanding warrants, convertible preferred stock (Series B, C, D), and convertible notes, could result in substantial dilution to existing stockholders.
• Warrants are accounted for as a liability, with changes in fair value reported in earnings, which may cause volatility in financial statements and adversely affect the market price of common stock.

Risks

• Certain important patents for Ameluz expired in 2019, which may lead to generic competition, significant price reductions, and loss of market share.
• The business depends substantially on the success of Ameluz; failure to obtain and maintain regulatory approvals or reimbursement for existing and additional indications could materially harm the business.
• Reliance on a single unaffiliated contract manufacturer (and recently a second) for Ameluz production; failure to maintain these relationships or production issues could materially harm the business.
• Failure to manufacture Ameluz, RhodoLED Lamps, or other products in sufficient quantities, at acceptable quality and cost levels, or to comply with cGMP, could lead to commercialization delays or inability to meet market demand.
• Involvement in patent protection and marketing lawsuits, which could be expensive, time-consuming, and unsuccessful.
• Limited or unavailable insurance coverage and medical expense reimbursement in certain market segments for products could make sales difficult.
• Healthcare legislative changes may have a material adverse effect on the business and results of operations.
• Significant competition from other pharmaceutical and medical device companies, as well as existing treatments like simple curettage and cryotherapy.
• The results of research and development efforts are uncertain, with no assurance they will enhance the commercial success of products.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of operating losses and anticipates continued operating losses, with no guarantee of future profitability.
• Failure to obtain additional financing may hinder marketing efforts for Ameluz or the commercialization of other licensed products.
• Failure to maintain an effective system of internal controls may impair the ability to produce timely and accurate financial statements, leading to a loss of investor confidence and a decline in stock price.
• Failure to maintain compliance with applicable Nasdaq listing standards could result in the delisting of common stock and publicly-traded warrants.
• Delay or termination of planned clinical trials for expanding Ameluz indications would result in unplanned expenses and adversely impact developmental activities and commercial prospects.
• Outstanding warrants, Series B, Series C, and Series D Convertible Preferred Stock, and Notes, if exercised or converted, could substantially increase the number of shares eligible for future resale and result in dilution to stockholders.
• Future sales and issuances of common stock or rights to purchase common stock, including pursuant to equity incentive plans, could result in additional dilution and cause the stock price to decline.
• Charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of the stock.
• The amended and restated certificate of incorporation's exclusive forum provision could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Warrants accounted for as a liability, with changes in fair value reported in earnings, may have an adverse effect on the market price of common stock.

Future Outlook

The company's strategy focuses on expanding Ameluz sales in the U.S., leveraging potential future approvals and label extensions for pipeline products, and strategically managing its portfolio by opportunistically adding complementary products or services. It plans to continue clinical development for Ameluz, with several trials expected to report results or begin enrollment in 2026 and 2027. The company anticipates continued operating losses and intends to retain all future earnings for business development and expansion, with no plans to pay dividends in the foreseeable future.

Management Comments

• Our principal objective is to improve patient outcomes by increasing the sales of our products.
• By executing our three strategic objectives, we will fuel company growth, deepen our trusted relationships in the dermatology community, and above all, help patients live healthier, more fulfilling lives.

Industry Context

Biofrontera operates in the biopharmaceutical sector, specifically targeting dermatological conditions with a focus on photodynamic therapy (PDT). The company's primary product, Ameluz, addresses actinic keratoses (AK), a condition affecting approximately 58 million Americans annually. The AK treatment market is estimated at $4 billion, but PDT currently holds a small share (2% or $100 million), with cryotherapy dominating (86%) and topical medications accounting for 12%. Biofrontera aims to expand its PDT market share and convert a portion of the cryotherapy market, particularly for treatments involving more than 14 lesions, where Ameluz PDT could be more effective. The company faces competition from established treatments and other PDT providers like Levulan and Blu-U.

Comparison to Industry Standards

• Ameluz PDT therapy demonstrates high efficacy, with patients experiencing up to 91% clearance after one or two treatments and limited or no scarring, which compares favorably to traditional treatments.
• International treatment guidelines strongly recommend photodynamic therapy for multiple AK and suggest it for single AK, indicating its recognized clinical value.
• Cryotherapy, the most common treatment (86% market share), is noted as potentially less effective and may leave scarring, suggesting Ameluz PDT offers a superior patient outcome in certain cases, particularly for field-directed therapy.

Management Changes

Corporate Governance

Legal Proceedings

• The company has been, and currently is, involved in both bringing and defending lawsuits related to patent protection and marketing of its products, and may become involved in similar suits in the future.

Related Party Transactions

• On October 20, 2025, the company finalized agreements to acquire all U.S. rights to Ameluz and RhodoLED from the Biofrontera Group (Biofrontera AG and its consolidated subsidiaries), which is a related party.
• As part of the Acquisition Agreement, the company issued 3,019 shares of Series D Convertible Preferred Stock to Biofrontera AG.
• As of December 3, 2025, Biofrontera AG holds approximately 3.4% of the outstanding shares of common stock and 3,019 shares of Series D Preferred.

Stakeholder Impact

• Shareholders face significant dilution risk from the conversion of various outstanding preferred stock, warrants, and convertible notes, as well as potential stock price volatility and the risk of delisting from Nasdaq. No dividends are anticipated in the foreseeable future.
• Employees may benefit from continued R&D efforts and potential label expansion for products, which could lead to job stability and growth opportunities. Equity incentive plans are in place.
• Customers (dermatologists and patients) could benefit from expanded product offerings, including the RhodoLED XL lamp, increased Ameluz dosage, potential new indications (e.g., superficial basal cell carcinoma, acne), and improved formulations, offering more effective and convenient treatment options.
• Creditors face heightened risk due to the explicit statement of 'substantial doubt about our ability to continue as a going concern.'
• Suppliers and manufacturers, particularly the contract manufacturers for Ameluz, are critical to the company's operations, and any failure in these relationships or production could severely impact the business.

Next Steps

• CSR for Ameluz moderate to severe acne treatment phase expected Q2 2026.
• CSR for Ameluz Actinic Keratosis trunk & extremities treatment phase expected Q2 2026.
• CSR for Ameluz Actinic Keratosis trunk & extremities PK-study expected Q2 2026.
• Plan to start enrollment for Ameluz combination daylight and conventional PDT trial in 2027.
• Plan to start enrollment for Ameluz squamous cell carcinoma in situ trial in 2027.
• The company will continue efforts to maintain compliance with Nasdaq listing standards to avoid delisting.

Key Dates

Recommendation

The filing highlights severe financial distress, including 'substantial doubt about our ability to continue as a going concern' and a history of operating losses with no clear path to profitability. The significant potential for dilution from numerous outstanding convertible securities and warrants, coupled with the company receiving no proceeds from the current offering, further exacerbates the financial risk. The Nasdaq delisting notice adds to the uncertainty. While strategic moves like acquiring full product rights and expanding indications are positive, they are overshadowed by the fundamental financial instability and the immediate dilution impact. Investors face a high risk of capital loss and further share price decline.

Keywords

Biofrontera, BFRI, S-1, SEC filing, common stock, resale, selling stockholders, Series C Preferred Stock, private placement, biopharmaceutical, dermatology, photodynamic therapy, PDT, Ameluz, RhodoLED, actinic keratoses, AK, skin cancer, squamous cell carcinoma, Xepi, ozenoxacin, clinical trials, FDA approval, patent protection, Nasdaq, emerging growth company, smaller reporting company, dilution, going concern, operating losses, competition, delisting risk, corporate governance, warrants, convertible notes